Document is current
Any future updates will be listed below
-
Authors
Mendes, Bárbara B. https://orcid.org/0000-0001-8630-1119
Zhang, Zilu https://orcid.org/0009-0000-2180-5957
Conniot, João
Sousa, Diana P. https://orcid.org/0000-0003-3474-5417
Ravasco, João M. J. M.
Onweller, Lauren A. https://orcid.org/0009-0004-0865-4495
Lorenc, Andżelika https://orcid.org/0000-0002-1474-7864
Rodrigues, Tiago https://orcid.org/0000-0002-1581-5654
Reker, Daniel https://orcid.org/0000-0003-4789-7380
Conde, João https://orcid.org/0000-0001-8422-6792
- License Information
-
More Information
Article History
Received: 3 May 2023
Accepted: 10 April 2024
First Online: 15 May 2024
Competing interests
: J. Conde and T.R. are co-founders and shareholders of TargTex SA Targeted Therapeutics for Glioblastoma Multiforme. J. Conde is a member of the Global Burden of Disease (GBD) consortium from the Institute for Health Metrics and Evaluation (IHME), University of Washington, USA, and member of the Scientific Advisory Board of Vector Bioscience, Cambridge. T.R. acts as a consultant to the pharmaceutical, biotechnology and technology industry and is a full member of the Acceleration Consortium, University of Toronto. D.R. acts as a consultant to the pharmaceutical and biotechnology industry, as a scientific mentor for Start2 and serves on the scientific advisory board of Areteia Therapeutics. The other authors declare no competing interests.
